Korean Circ J.  2012 Sep;42(9):592-594. 10.4070/kcj.2012.42.9.592.

Anti-Inflammatory Effects of Statins Beyond Cholesterol Lowering

• Joo SJ

• KMID: 2297888
• DOI: http://doi.org/10.4070/kcj.2012.42.9.592

Abstract

No abstract available.

MeSH Terms

Cholesterol
Cholesterol

Reference

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005. 366:1267–1278.

2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005. 352:1425–1435.

3. Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis. J Atheroscler Thromb. 2011. 18:351–358.

4. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004. 350:1387–1397.

5. Emerging Risk Factors Collaboration. Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010. 375:132–140.

6. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 2009. 203:325–330.

7. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005. 352:29–38.

8. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005. 46:1855–1862.

9. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007. 49:2003–2009.

10. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006. 48:438–445.

11. Peters SA, Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med. 2010. 268:155–161.

12. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008. 359:2195–2207.

13. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010. 106:204–209.

14. Kim YR, Park JH, Lee HJ, Pyun WB, Park SH. The effect of doubling the statin dose on pro-inflammatory cytokine in patients with triple-vessel coronary artery disease. Korean Circ J. 2012. 42:595–599.

15. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005. 352:20–28.

16. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009. 373:1175–1182.